Form 4: Sensei Biotherapeutics Executive Reports Stock Transaction
SEC Form 4 Filing
Edward van der Horst, Chief Scientific Officer of Sensei Biotherapeutics, reports disposition of shares to cover tax obligations and holdings including shares purchased through the employee stock purchase plan.
Summary
- On February 19, 2025, Edward van der Horst, the Chief Scientific Officer of Sensei Biotherapeutics, engaged in a transaction involving common stock.
- 2,276 shares were disposed of to satisfy withholding tax obligations upon the vesting of restricted stock units at a price of $0.476 per share.
- Following the transaction, van der Horst beneficially owns 59,794 shares of common stock, which includes 6,000 shares purchased since May 16, 2024, through the company's Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine stock transaction. It doesn't convey any particularly positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their stock transactions. It's a standard practice for executives to manage their stock holdings for tax and diversification purposes.
Key Dates
| Date | Description |
|---|---|
| May 16, 2024 | Start date for shares purchased through the Employee Stock Purchase Plan. |
| February 19, 2025 | Date of the stock transaction (disposal of shares for tax obligations). |
| February 26, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.